First Austrian biotech company to develop a cancer immunotherapy product through to market
Approval in 2017 of APN311 for treatment of pediatric neuroblastoma in EU and other countries,
US/Japan BLA filing in preparation
Respiratory drug candidate APN01 in clinical development
Oncology pipeline in clinical stages
Lead by highly experienced and motivated team with global background
Inhalation of APN01 to directly target SARS-CoV-2 virus in respiratory tract, the lung and tissue itself Primary objective is to evaluate safety and tolerability of inhaled APN01 Phase 1 trial to enroll about 40 healthy volunteers Additional US Phase 2 trial with intravenous administration of APN01 Press release (EN) | Presseaussendung (DE)
Despite recent advances in the treatment of cancer, the disease remains a leading cause of death by disease worldwide1. It is reported that one in two people will be diagnosed with cancer in their lifetime2, resulting in a stronger-than-ever drive for new efficacious therapies. Our growing knowledge of cancer enables us to develop new technologies...
Prof. Josef Penninger 1. Do you remember your first "encounter" with the ACE2 molecule ? I remember well, it was in the hallway of the Ontario Cancer Institute. My postdoc Mike Crackower had just cloned the second ACE, hence ACE2. That was around 1998/1999. 2. Which physiological role does ACE2 have within the RAAS ?...